Discordant regulation of transforming growth factor-beta receptors by prostaglandin E2.
The effect of PGE2 on TGF-beta receptor binding was assessed for both signaling (type I and type II) and non-signaling (type III) TGF-beta receptors. We found in cross-linking studies that PGE2 treatment (24 h) decreased binding of TGF-beta to the type I and type II receptors by approx. 50% and markedly increased binding of TGF-beta to type III receptors nearly 10-fold. Northern analyses indicated that PGE2 decreased type I receptor mRNA levels by approximately 30-50%, decreased type II receptor mRNA levels by approximately 60%, and markedly increased type III receptor mRNA levels. Coincubation with cycloheximide partially blocked the PGE2-induced inhibition of type II receptor mRNA. In contrast, cycloheximide minimally affected PGE2-induced type III receptor mRNA levels. Activation of protein kinase C by phorbol esters had no apparent effect on TGF-beta receptor mRNA levels. Our data suggest that alterations in TGF-beta receptor expression could modify the response of tissues to TGF-beta during injury.
Fine
A
A
Pulmonary Center, Boston University School of Medicine, MA 02118.
Panchenko
M P
MP
Smith
B D
BD
Yu
Q
Q
Goldstein
R H
RH
D000818:Animals; D002478:Cells, Cultured; D018076:DNA, Complementary / Q000235:genetics; D015232:Dinoprostone / Q000502:physiology*; D005347:Fibroblasts / Q000378:metabolism; D006801:Humans; D008168:Lung; D010957:Plasmids; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D018125:Receptors, Transforming Growth Factor beta / Q000145:classification / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis; D016212:Transforming Growth Factor beta / Q000378:metabolism*
D018076:DNA, Complementary; D012333:RNA, Messenger; D018125:Receptors, Transforming Growth Factor beta; D011993:Recombinant Fusion Proteins; D016212:Transforming Growth Factor beta; D015232:Dinoprostone